The FDA assigned INO-3107 a Prescription Drug User Fee Act (PDUFA) review goal date of October 30, 2026, which is the date by which it intends to take action on the application. The FDA has indicated ...

A novel oral antibiotic zoliflodacin is as effective as ceftriaxone plus azithromycin in treating uncomplicated urogenital ...

In the EPCORE DLBCL-3 study, fixed-duration epcoritamab monotherapy delivered deep, durable responses with manageable ...

The possibility of a long-awaited change in the treatment of male baldness has been raised by Cosmo Pharmaceuticals’ ...

For patients with relapsed or refractory multiple myeloma, treatment with teclistamab plus daratumumab is associated with a significant PFS benefit.

Doctors are urging San Diegans to not ignore their heart health during the holidays, as research shows this time of year sends more people to the emergency room with heart-related issues than any ...

Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...

Trodelvy showed fewer severe side effects, such as neutropenia and diarrhea, compared to chemotherapy in untreated TNBC ...

Combination therapy with a nonsteroidal mineralocorticoid receptor antagonist and an SGLT2 inhibitor reduced albuminuria more ...

These 25 films from 2025, hailing from all across the globe, represent the very best of what documentary cinema has to offer.

I have a bad habit of telling myself I am just browsing, then somehow ending up reinstalling a 100-hour RPG. This Christmas ...

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings ...